She will be all right, Matt is on the board from BOT and they already have past phase 1 (and 2) on the bioavailability for synthetic CBD. No doubt they will have leverage the lessons learned for further success at EMD. (also why have we gone down a synthetic path for FDA - they are much happier around production & purity).
Good luck holders. One phase 1 into 2x phase 3 - ripper.
